Cobimetinib Fumarate

可美替尼

Report date: 2022/08/19 16:45:24
NME

Base Information

Drug NameCobimetinib Fumarate
Drug Alias Name考美替尼Cobimetinib考比替尼CobimetinibumCotellic +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase 1 inhibitorsDual specificity mitogen-activated protein kinase kinase 2 inhibitors
TargetsDual specificity mitogen-activated protein kinase kinase 2Dual specificity mitogen-activated protein kinase kinase 1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungMelanoma +[4] 
Global Approved IndicationsMelanoma
Approved Indications in ChinaN/A
Original Approved Country/TerritorySwitzerland
Original Approved Date2015/02/27
Country/TerritoryCzechiaBelgiumCanada +[21] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesExelixis Inc
China Registration ClassN/A

Develop Information

Active CompaniesUtah State UniversityF. Hoffmann-La Roche LtdExelixis Inc +[6] 
Inactive CompaniesGeorgetown University
Active IndicationsSolid tumoursMelanomaLeukemia, Myelomonocytic, Chronic
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeL01EE02
Related LinksWikipediaDrugBankKEGG